Article Versions Notes

Karwaciak I, Sałkowska A, Karaś K, Sobalska-Kwapis M, Walczak-Drzewiecka A, Pułaski Ł, Strapagiel D, Dastych J, Ratajewski M. SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib. Cancers. 2019; 11(5):673. https://doi.org/10.3390/cancers11050673

Karwaciak, Iwona, Anna Sałkowska, Kaja Karaś, Marta Sobalska-Kwapis, Aurelia Walczak-Drzewiecka, Łukasz Pułaski, Dominik Strapagiel, Jarosław Dastych, and Marcin Ratajewski. 2019. "SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib" Cancers 11, no. 5: 673. https://doi.org/10.3390/cancers11050673

Karwaciak, I., Sałkowska, A., Karaś, K., Sobalska-Kwapis, M., Walczak-Drzewiecka, A., Pułaski, Ł., Strapagiel, D., Dastych, J., & Ratajewski, M. (2019). SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib. Cancers, 11(5), 673. https://doi.org/10.3390/cancers11050673